SCHEMBL16631577

SCHEMBL16631577

Cc1[nH]c(=O)ccc1[C@@H]1O[C@H](CO)C(O)[C@@H]1F

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 0.40
SLC28A2 O43868 1/20 0.40
SLC29A1 Q99808 1/20 0.40
SLC28A3 Q9HAS3 1/20 0.40
CDA P32320 1/20 0.38
SLC5A2 P31639 10/20 0.37
ALDH1A1 P00352 2/20 0.37
EPHX2 P34913 1/20 0.35
OGA O60502 1/20 0.34
HEXB P07686 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
P2RY14 Q15391 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17082394 0.88 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL18871288 0.88 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL16631246 0.88 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL16781808 0.88 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL16805397 0.88 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL16781803 0.88 SLC28A1 (0.46) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL16631525 0.85 SLC28A1 (0.41) SLC28A1SLC28A2SLC29A1SLC28A3CDA
SCHEMBL16631431 0.82 SLC28A1 (0.39) SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2
SCHEMBL18079912 0.82 SLC28A3 (0.37) SLC28A1SLC28A2SLC29A1SLC28A3CDA
SCHEMBL16631173 0.81 SLC28A1 (0.38) SLC28A1SLC28A2SLC29A1SLC28A3CDA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SLC28A1 302/4885SLC28A2 214/4885SLC29A1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.